Patents Examined by M Franco G Salvoza
  • Patent number: 10927150
    Abstract: Provided herein are modified recombinant adeno-associated virus (rAAV) capsid proteins, such as modified rAAV1, rAAV5, and rAAV6 capsid proteins, rAAV particles comprising such capsid proteins, nucleic acid molecules encoding such capsid proteins, as well as compositions, kits and methods of use thereof.
    Type: Grant
    Filed: September 9, 2019
    Date of Patent: February 23, 2021
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: George Vladimirovich Aslanidi, Kim M. Van Vliet, Mavis Agbandje-McKenna, Arun Srivastava
  • Patent number: 10913987
    Abstract: The system described herein for bacterial identification can be used as a point-of-care or lab-based diagnostic system. In some implementations, the system can be used to detect other foreign agents within blood or other samples. The system can include disposable microfluidic cartridges that are removable from the system. The microfluidic cartridges can receive a sample, such as a blood sample, that is suspected of containing bacterial cells and separate the bacterial cells from the blood sample. Once the bacterial cells are separated from the blood, the system can introduce the recombinant detector bacteriophages into the system that can infect the bacterial cells. The system can then detect the expression of reporter genes from the recombinant detector bacteriophages.
    Type: Grant
    Filed: March 27, 2017
    Date of Patent: February 9, 2021
    Assignee: The Charles Stark Draper Laboratory, Inc.
    Inventors: Jason W. Holder, Jason O. Fiering
  • Patent number: 10894832
    Abstract: This invention concerns anti-inflammatory agents, compositions, and methods for treating inflammatory disorders.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: January 19, 2021
    Assignee: The Rockefeller University
    Inventors: Jeffrey V. Ravetch, Andrew Pincetic
  • Patent number: 10883980
    Abstract: The present invention provides a method of inhibiting hepatitis E virus (HEV) release from a cell that is infected with an HEV, and a method of treating a HEV infection in a subject in need thereof. The present invention also provides a method of identifying agent that inhibits HEV infectivity using a transcomplementation system.
    Type: Grant
    Filed: September 21, 2017
    Date of Patent: January 5, 2021
    Assignee: The Trustees of Princeton University
    Inventors: Alexander Ploss, Qiang Ding
  • Patent number: 10870683
    Abstract: The present application relates to novel HIV-1 envelope glycoproteins which may be utilized as an HIV-1 vaccine immunogens, antigens for crystallization and for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: December 22, 2020
    Assignees: INTERNATIONAL AIDS VACCINE INITIATIVE, THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Viktoriya Dubrovskaya, Francisco Javier Guenaga, Richard Wyatt
  • Patent number: 10869922
    Abstract: The invention belongs to the field of biological medicine, in particular refers to an alhydrogel-sodium chloride compound immunologic adjuvant, preparation method and use thereof. The technical problem to be solved by the invention is to provide a well-behaved and novel immunologic adjuvant. The technical solution for solving the technical problem of the invention is to provide the use of sodium chloride in preparing immunologic adjuvant and the alhydrogel-sodium chloride compound immunologic adjuvant obtained on the basis thereof. The compound immunologic adjuvant mainly includes alhydrogel and sodium chloride. The alhydrogel-sodium chloride compound immunologic adjuvant of the invention is an excellent compound immunologic adjuvant, which can be used for various antigens, and provides a new and effective choice for the development and application of vaccines due to the advantages of simple and convenient use, low cost, strong immune activity, high clinical safety and the like.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: December 22, 2020
    Assignee: SICHUAN UNIVERSITY
    Inventors: Xiawei Wei, Min Luo, Yuquan Wei
  • Patent number: 10869921
    Abstract: Polyvalent, primary isolate nucleic acid compositions for inducing an immune response against HIV are disclosed. The compositions and methods described herein are for the use of a nucleic acid composition that encodes one or more different HIV envelope glycoproteins. The synthetic, codon-optimized DNAs encoding one or more HIV proteins are a combination of different nucleic acids, such as DNA plasmids, generated from primary isolate DNA of different HIV major group genetic clades and/or different proteins. HIV polypeptide compositions for inducing an immune response against HIV are also disclosed. Methods for using the polypeptide compositions before, at the same time as, and/or after administration of the DNA compositions are provided.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: December 22, 2020
    Assignee: University of Massachusetts
    Inventors: Shan Lu, Shixia Wang
  • Patent number: 10858631
    Abstract: The invention relates to an adeno-associated virus (AAV) producer cell comprising nucleic acid sequences encoding: rep/cap gene; helper virus genes; and the DNA genome of the AAV vector particle, wherein the nucleic acid sequences are all integrated together at a single locus within the AAV producer cell genome. The invention also relates to nucleic acid vectors comprising a non-mammalian origin of replication and the ability to hold at least 25 kilobases (kb) of DNA, characterized in that the nucleic acid vectors comprise nucleic acid sequences encoding: rep/cap gene, and helper virus genes. The invention also relates to uses and methods using the nucleic acid vectors in order to produce stable AAV packaging and producer cell lines.
    Type: Grant
    Filed: April 18, 2018
    Date of Patent: December 8, 2020
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventor: Conrad Vink
  • Patent number: 10851167
    Abstract: This invention concerns anti-inflammatory agents, compositions, and methods for treating inflammatory disorders.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: December 1, 2020
    Assignee: The Rockefeller University
    Inventors: Jeffrey V. Ravetch, Andrew Pincetic
  • Patent number: 10835598
    Abstract: An experiment has shown that ranpirnase is a microbicide. It is believed that topical application of a topical pharmaceutical composition consisting essentially of a prophylactically effective concentration of an enzymatically-active ribonuclease (e.g. ranpirnase) and a viscous vehicle that does not unacceptably interfere with the enzymatic activity (e.g. K-Y® Brand Jelly) will prophylactically protect an individual from a sexually-transmitted viral infection, particularly HIV. It is also believed that e.g. ranpirnase can be delivered to tissues of an individual who is to be prophylactically protected against viral infections by transfecting ranpirnase DNA into human microbiota and exposing the individual to the thus-modified human microbiota. It is also believed that ranpirnase can be delivered to a woman who is to be prophylactically protected against a sexually-transmitted viral infection by use of an intravaginal ring that has been impregnated with ranpirnase.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: November 17, 2020
    Assignee: ORGENESIS INC.
    Inventors: Jamie Sulley, Luis Squiquera, David Sidransky, Tom Hodge
  • Patent number: 10835599
    Abstract: The present invention relates, in general, to an HIV-1 vaccine and, in particular, to a B cell lineage-based vaccination protocol.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: November 17, 2020
    Assignees: DUKE UNIVERSITY, CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Barton F. Haynes, Garnett Kelsoe, Stephen Harrison, Thomas B. Kepler
  • Patent number: 10835600
    Abstract: The present invention relates to the use of a composition in a method of reducing the allergenicity of a cat. Moreover, the present invention relates to the use of a composition in a method of reducing the allergenicity of a cat for a human exposed to the cat. Furthermore, the present invention relates to compositions comprising a virus-like particle (VLP) and at least one Fel d1 protein. The compositions of the invention induce efficient immune responses, in particular antibody responses, in cats and are useful for the treatment and/or prevention of cat allergy.
    Type: Grant
    Filed: September 7, 2016
    Date of Patent: November 17, 2020
    Assignee: UNIVERSITÄT ZÜRICH
    Inventors: Martin Bachmann, Gary Jennings, Thomas Kündig, Gabriela Senti, Franziska Zabel
  • Patent number: 10822397
    Abstract: This invention provides antibodies or fragments thereof that are capable of specifically binding to at least one conformational epitope of Human Enterovirus 71 (EV71), wherein the antibody individually comprises at least one variable light chain and at least one variable heavy chain. There is also provided a method of producing an antibody capable of specifically binding to at least one conformational epitope of Human Enterovirus 71 (EV71).
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: November 3, 2020
    Assignee: MAB Explorations Sdn Bhd
    Inventor: Mary Jane Cardosa
  • Patent number: 10813977
    Abstract: Compositions, methods and kits are provided for treating complement related disorders in a subject with protein in combination having protein fusions of at least two of a CD46 protein, a CD55 protein and a CD59 protein or with a recombinant chimeric protein having at least two of a CD46 protein, a CD55 protein and a CD59 protein or with nucleic acids encoding these proteins. The composition negatively modulates classical and alternative complement pathways thereby treating complement related disorder such as macular degeneration, age-related macular degeneration, diabetic retinopathy, inflammatory bowel disease, thyroiditis, cryoglobulinaemia, fetal loss, organ graft rejection, cancer, etc.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: October 27, 2020
    Assignee: Trustees of Tufts College
    Inventors: Rajendra Kumar-Singh, Derek Leaderer, Siobhan Cashman
  • Patent number: 10806781
    Abstract: Embodiments herein relate to compositions of and methods for live attenuated alphaviruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated alphaviruses and compositions to reduce inactivation and/or degradation of the live, attenuated alphavirus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated alphavirus composition may include HEPES buffer. In other embodiments, the HEPES buffer may further include a carbohydrate and gelatin and/or a salt.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: October 20, 2020
    Assignee: Takeda Vaccines, Inc.
    Inventors: Dan T. Stinchcomb, Jill A. Livengood, Laszlo Varga
  • Patent number: 10806779
    Abstract: Described are methods for preparing virosomes comprising the steps of: (a) providing an enveloped virus, and optionally inactivating the virus; (b) solubilizing the viral envelopes in a first solubilizing agent; (c) pre-solubilizing exogenous components in a second solubilizing agent; (d) adding the pre-solubilized exogenous components to the solubilized viral envelopes; and (e) reconstituting virosomal membranes by removing the solubilizing agent. According to the disclosure, the viral envelopes and the exogenous components are (pre-)solubilized at a temperature below 33° C.
    Type: Grant
    Filed: June 30, 2014
    Date of Patent: October 20, 2020
    Assignee: JANSSEN VACCINES & PREVENTION B.V.
    Inventors: Wenyu Dong, Pieter Rijken, Mike Ugwoke
  • Patent number: 10799568
    Abstract: The present invention relates to adenoviral vectors, wherein the viral capsid has been coated with polypeptides, which are capable of stimulating a peptide-specific immune response in a subject and uses thereof. Furthermore, the present invention relates to methods of treating diseases, e.g. cancer, by adenoviral vectors which have been coated by polypeptides causing peptide-specific immune response. Also the present invention relates to a method of coating adenoviral vectors by specific peptides as well as to a method of identifying those peptides suitable for coating the capsid of an adenoviral vector.
    Type: Grant
    Filed: May 18, 2015
    Date of Patent: October 13, 2020
    Assignee: VALO THERAPEUTICS OY
    Inventors: Vincenzo Cerullo, Markus Vähä-Koskela, Mari Hirvinen, Cristian Capasso
  • Patent number: 10781459
    Abstract: Provided herein are methods related to co-packaging of multiple rAAV particles, e.g., by introducing multiple nucleic acid vectors encoding proteins or polypeptides or RNAs of interest into a single cell preparation.
    Type: Grant
    Filed: June 20, 2015
    Date of Patent: September 22, 2020
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Barry John Byrne, Phillip A. Doerfler, Nathalie Clement
  • Patent number: 10781427
    Abstract: The present invention relates to recombinant adenoviruses and vectors thereof. In particular, the adenoviruses are novel simian adenoviruses having a low seroprevalence and high immunogenicity relative to other adenoviruses and vectors thereof. The invention also provides methods for production of the adenoviruses and for the treatment of diseases by administering the adenoviral vector(s) to a subject (e.g., a human).
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: September 22, 2020
    Assignees: Beth Israel Deaconess Medical Center, Inc., Washington University
    Inventors: Dan H. Barouch, Herbert Virgin, IV, Peter Abbink
  • Patent number: 10772951
    Abstract: The present disclosure concerns an oncolytic virus for the treatment of cancer, such as in brain cancer, for example glioblastoma. The oncolytic virus may exhibit reduced levels of neurotoxicity. The oncolytic virus may be an isolated viral particle capable of producing a cDNA polynucleotide that includes a sequence according to SEQ ID NO: 1 when the virus is in a host cell. The oncolytic virus may be an isolated viral particle that includes an RNA polynucleotide that includes a sequence according to SEQ ID NO: 2. The oncolytic virus may be an isolated viral particle having a genome that includes open reading frames that encode: proteins having sequences comprising SEQ ID NOs: 3, 4, 5, 6 and 7; or variants thereof.
    Type: Grant
    Filed: May 16, 2016
    Date of Patent: September 15, 2020
    Assignee: CHILDREN'S HOSPITAL OF EASTERN ONTARIO RESEARCH INSTITUTE INC.
    Inventor: David F. Stojdl